In this April 10, 2020 photo, a staff member shows an inactivated COVID-19 vaccine sample at a production unit of the China National Biotec Group. (PHOTO / XINHUA)

BEIJING - Health authorities of the Republic of Peru have approved a phase 3 clinical trial for a potential COVID-19 vaccine developed by China National Biotec Group (CNBG), the company said on Thursday in Chinese social media platform Weibo.

The experimental vaccine of CNBG, a unit of state-owned pharmaceutical giant China National Pharmaceutical Group (Sinopharm), has already entered phase 3 testing in the United Arab Emirates.

Phase 3 trials, which usually involve several thousand participants, allow researchers to gather data on the efficacy of potential vaccines for final regulatory approvals.

ALSO READ: UAE to host phase 3 trials for Chinese vaccine